TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06149260
Drug: Semaglutide Pen Injector
Normalized name: semaglutide Pen Injector
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and then maintained 0.5mg until the end of treatment in total 24 weeks.
Study: NCT05954897
Drug: Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RALOX Regimen of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Tislelizumab
Study: NCT06151262
Drug: Trilaciclib+mFOLFIRINOX
Normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This was a single-arm, exploratory study of the combination of Trilaciclib and mFOLFIRINOX in patients with advanced pancreatic cancer receiving first-line therapy. Observed the incidence of chemotherapy-induced myelosuppression, and imaging was performed every four cycles to assess tumor response.
Study: NCT05290129
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
Study: NCT04634162
Drug: Cangrelor
Normalized name: Cangrelor
DrugBank: Cangrelor (DB06441)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The duration of cangrelor/placebo infusion will be 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
Study: NCT05190575
Drug: TST001
Normalized name: IMMUNOGLOBULIN G1, ANTI-(HUMAN CLAUDIN 18.2) (HUMAN-MUS MUSCULUS MONOCLONAL TST001 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL TST001 .KAPPA.-CHAIN, DIMER
DrugBank: Osemitamab (DB18219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TST001 IV infusion every 3 weeks until disease progression or other discontinuation criteria.
Study: NCT06221111
Drug: Rimegepant 75 MG [Nurtec]
Normalized name: rimegepant 75 MG [Nurtec]
DrugBank: Rimegepant (DB12457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo controlled trial
Study: NCT04916197
Drug: Dexmedetomidine prolonged sedation
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine for 24h after patients finished endovascular thrombectomy and returned to ICU.
Study: NCT05005312
Drug: PF-07321332
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT05005312
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PK Boosting agent
Study: NCT06207344
Drug: Dexmedetomidine and propofol
Normalized name: Propofol
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group 1: After anesthesia induction, dexmedetomidine was infused at 1 μg/kg intravenously within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. Meantime, propofol was infused at 4-12mg/kg/h intravenously to maintain the depth of anesthesia.
Study: NCT06207344
Drug: Dexmedetomidine and desflurane
Normalized name: Desflurane
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group 2: After anesthesia induction, dexmedetomidine was infused at 1 μg/kg intravenously within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. At the same time, 2.5%-8.5% desflurane was inhaled to maintain the depth of anesthesia.
Study: NCT05798026
Drug: EU103
Normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: EU103 will be administered via intravenous infusion.
Study: NCT05204524
Drug: Temozolomide for injection combined with epirubicin
Normalized name: epirubicin Injection
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Temozolomide for injection, according to the requirements of GCP, the test drug should be sealed, kept away from light and kept at 2-8℃, with a valid period of 24 months.
Study: NCT05282706
Drug: Lavender Oil
Normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A hydrogel lavender oil infused aromatherapy patch
Study: NCT05282706
Drug: Peppermint oil
Normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A hydrogel peppermint oil infused aromatherapy patch
Study: NCT05193994
Drug: Dolutegravir, Abacavir and Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dolutegravir 50mg, Abacavir 600mg and Lamivudine 300mg.
Study: NCT06489626
Drug: Dexamethasone injection
Normalized name: dexamethasone Injection
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 milligram intravenous dexamethasone will be administered intraoperatively
Study: NCT05546788
Drug: hydroxylated poly methoxy flavones
Normalized name: flavone
DrugBank: Flavone (DB07776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Received hydroxylated poly methoxy flavones extract solid dispersion incorporated into sodium carboxymethylcellulose gel
Study: NCT05546788
Drug: chlorhexidine
Normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Received chlorhexidine gel
Study: NCT06338202
Drug: Mavacamten
Normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As detailed in the product label
Study: NCT06673329
Drug: Brodalumab
Normalized name: Brodalumab
DrugBank: Brodalumab (DB11776)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brodalumab 210 mg subcutaneous injection
Study: NCT04267237
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab 1680 mg will be administered by intravenous (IV) infusion on Day 1 of Cycles 1-12.
Study: NCT04872985
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg orally once per day. Pyrotinib starts with a dose of 240 mg once daily for one week, followed by 320 mg once daily for the next week, before transitioning to 400 mg once daily as maintenance therapy.
Study: NCT04872985
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m2,q3W\*4
Study: NCT04872985
Drug: Doxorubicin Hydrochloride Liposome Injection
Normalized name: doxorubicin hydrochloride liposome Injection
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mg/m2, q3w\*4
Study: NCT04872985
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m2, q3w\*4
Study: NCT04872985
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 120mg/m2 qw\*12 or 260mg/m2 q3w\*4
Study: NCT05730439
Drug: Nicotine Oral Pouch
Normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receive ZYN brand NP
Study: NCT05730439
Drug: Nicotine Oral Pouch
Normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receive Rogue brand NP
Study: NCT05730439
Drug: Smokeless Tobacco
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive usual SLT
Study: NCT06350162
Drug: Serplulimab
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5mg/kg,IV over 30 minutes +/- 10 minutes on day 1. Cycles repeat every 21 days.
Study: NCT04354025
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: -Fludarabine (dose: 30 mg/m\^2 per dose) will be given daily beginning on Day -7 for a total of 5 doses administered as an IV infusion over 30 minutes.
Study: NCT04354025
Drug: Ara-C
Normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: -Ara-C (dose: 2000mg/m\^2 per dose) will be given daily for a total of 5 doses administered as IV infusion over 3 hours, starting the same day as fludarabine.
Study: NCT04354025
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: -Filgrastim (dose: 5 mcg/kg per dose to a maximum of 300 mcg) will be given subcutaneously daily for a total of 5 doses starting the same day as fludarabine and ara-C.
Study: NCT04354025
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: -IL-2 will be administered subcutaneously at a dose of 1 million units/m2 every other day from Day 0 to Day +12 (7 doses total).
Study: NCT05105412
Drug: Lenalidomide and Gemcitabine (Dose level 11)
Normalized name: Lenalidomide
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lenalidomide 25 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
Study: NCT05105412
Drug: Lenalidomide and Gemcitabine (Dose level 21)
Normalized name: Lenalidomide
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lenalidomide 15 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
Study: NCT05351086
Drug: Dihydroergotamine (D.H.E 45)
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D.H.E. 45 is ergotamine hydrogenated in the 9, 10 position as the mesylate salt. It is supplied as a clear, colorless solution supplied in sterile ampules for IV, intramuscular, or subcutaneous administration containing (per mL) DHE mesylate, USP 1 mg, ethanol, 94% w/w. 6.2% by volume, glycerin 15% by weight, and water for injection.
Study: NCT06574269
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine
Study: NCT06535399
Drug: BMS-986369
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT04834986
Drug: Tislelizumab combined with Lenvatinib
Normalized name: Tislelizumab
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pre-operation: Tislelizumab, 200mg, iv,d1,q3w, 2-4 cycles; Lenvatinib,8mg/kg,po,qd,d1-d84.~Operation Postoperation: 4-8 weeks after surgery, Tislelizumab, 200mg, iv,d1,q3w; Lenvatinib,8mg/kg,po,qd, up to one year.
Study: NCT05105412
Drug: Lenalidomide and Gemcitabine (Dose level 31)
Normalized name: Lenalidomide
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lenalidomide 10 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
Study: NCT05105412
Drug: Lenalidomide and Gemcitabine (Dose level 41)
Normalized name: Lenalidomide
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lenalidomide 10 mg/day D1-D14 and gemcitabine 800 mg/m2 D1, D8
Study: NCT05204550
Drug: unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intranasal
Study: NCT05204550
Drug: 0.9%sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intranasal
Study: NCT06228092
Drug: neostigmine/glycopyrrolate
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia personnel will administer the drug as a bolus over 5 seconds in an intravenous catheter upon conclusion of anaesthesia with a TOF within the range from TOF count of 2 to a TOF ratio \< 0.60
Study: NCT06228092
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anesthesia personnel will administer the drug as a bolus over 5 seconds in an intravenous catheter upon conclusion of anaesthesia with a TOF within the range from TOF count of 2 to a TOF ratio \< 0.60
Study: NCT04798586
Drug: Elranatamab (PF-06863135)
Normalized name: elranatamab
DrugBank: Elranatamab (DB15395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCMA-CD3 bispecific antibody
Study: NCT06619561
Drug: Vimseltinib
Normalized name: Vimseltinib
DrugBank: Vimseltinib (DB17520)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05421897
Drug: Dinutuximab with Chemotherapy
DrugBank: Dinutuximab (DB09077)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rapid infusion of dinutuximab in 4 hours or less
Study: NCT05462587
Drug: AVTX-803 (L-Fucose)
Normalized name: L-FUCOSE
DrugBank: VTX-803 (DB18271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-fucose crystalline powder
Study: NCT06288113
Drug: Lutetium Lu 177 Vipivotide Tetraxetan
Normalized name: lutetium Lu 177 vipivotide tetraxetan
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05035186
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-H. pylori regimens
Study: NCT04652258
Drug: Actemra
Normalized name: Actemra
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dosage: 8mg/kg (max. 800mg) Actemra administered intravenously as an infusion over 60 min.
Study: NCT05015361
Drug: Remimazolam Tosilate
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment group A: Remimazolam Tosilate; high dose Treatment group B: Remimazolam Tosilate; low dose
Study: NCT05015361
Drug: Propofol Injection.
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment group C: Propofol Injection.
Study: NCT05041543
Drug: NTX-101
Normalized name: NTx-265
DrugBank: NTx-265 (DB05649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drops, topical administration
Study: NCT06255977
Drug: CN-105
Normalized name: CN-105
DrugBank: CN-105 (DB18345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of CN-105 will be administered as a slow IV bolus over 30 minutes.
Study: NCT04044534
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in this arm will receive intranasal insulin (80 IU per day).
Study: NCT06077422
Drug: bupivacaine liposome injectable suspension
Normalized name: bupivacaine liposome Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine liposome injectable suspension (Exparel) will be administered by ultrasound-guided ESP block, unilaterally if thoracotomy on ipsilateral side, bilaterally if median sternotomy.
Study: NCT06077422
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine HCl (Marcaine) will be administered by ultrasound-guided ESP block, unilaterally if thoracotomy on ipsilateral side, bilaterally if median sternotomy.
Study: NCT04928365
Drug: Anti-PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 therapy
Study: NCT00092911
Drug: DVS-233 SR
Normalized name: rAAVrh74.MHCK7.DYSF.DV
DrugBank: S-23 (DB07419)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06408194
Drug: CD22CART infusion
Normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CD22CART will be administered after Standard of Care (SOC) administration of tisagenlecleucel.
Study: NCT06408194
Drug: Tisagenlecleucel
Normalized name: Tisagenlecleucel
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All enrolled participants will receive lymphodepletion followed by standard of care tisagenlecleucel infusion.
Study: NCT04983901
Drug: Imipenem/Cilastatin/Relebactam
Normalized name: imipenem/cilastatin/relebactam
DrugBank: Cilastatin (DB01597)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04983901
Drug: Cefepime
Normalized name: Cefepime
DrugBank: Cefepime (DB01413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04983901
Drug: Meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04983901
Drug: Piperacillin-Tazobactam
Normalized name: piperacillin-tazobactam
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04983901
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04983901
Drug: Daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04983901
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or PO
Study: NCT05337124
Drug: LUPKYNIS
Normalized name: Lupkynis
DrugBank: Voclosporin (DB11693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LUPKYNIS treatment per the approved US Prescribing Information
Study: NCT05502081
Drug: Casirivimab and Imdevimab Drug Combination
DrugBank: Imdevimab (DB15940)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: antiviral Monoclonal Antibodies
Study: NCT05914272
Drug: Osmotic drugs
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients had used osmotic drugs within 72 hours of admission.
Study: NCT06017323
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 IV given days 1, 8, and 15every 28 days (1 cycle)
Study: NCT06017323
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg/m2 given days 1, 8, and 15every 28 days (1 cycle)
Study: NCT06017323
Drug: Proglumide Dose level 1
Normalized name: proglumide
DrugBank: Proglumide (DB13431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 1200 mg orally given as400 mg orally (PO), three times a day(TID) (dose level 1)
Study: NCT06017323
Drug: Proglumide Dose level 2
Normalized name: proglumide
DrugBank: Proglumide (DB13431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 1600 mg orally given as800 mg orally (PO) twice a day (BID)(dose level 2).
Study: NCT05502081
Drug: Remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: antiviral drug
Study: NCT00090649
Drug: DVS-233 SR
Normalized name: rAAVrh74.MHCK7.DYSF.DV
DrugBank: S-23 (DB07419)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05502081
Drug: Favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: antiviral drug
Study: NCT05883852
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer
Study: NCT05883852
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.
Study: NCT05883852
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab is a humanized monoclonal antibody derived from recombinant DNA,
Study: NCT05883852
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab is a recombinant humanized monoclonal antibody that specifically binds to the extracellular dimerization domain (subdomain Ⅱ) of epidermal growth factor receptor 2(HER2).
Study: NCT05883852
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin is an antineoplastic agent derived from doxorubicin.Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle.
Study: NCT03059173
Drug: Clomiphene Citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 50 mg. taking D2 to D6 of each cycle (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle and the dose will be increased if necessary.
Study: NCT04982549
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab (intravenous infusion)
Study: NCT04982549
Drug: Carboplatin/ Paclitaxel
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin /Paclitaxel, as per standard of care
Study: NCT04982549
Drug: Pemetrexed/ Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pemetrexed / Cisplatin, as per standard of care
Study: NCT04982549
Drug: Pemetrexed/ Carboplatin
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed / Carboplatin , as per standard of care
Study: NCT04909697
Drug: Sivelestat sodium
Normalized name: Sivelestat
DrugBank: Sivelestat (DB12863)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 4.8mg/kg sivelestat sodium was given in 50ml normal saline, and was continuously pumped in the dark for 24h, equivalent to 0.2mg/kg/h.Applied for 5 consecutive days
Study: NCT04909697
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50ml normal saline was continuously pumped in the dark for 24h. Applied for 5 consecutive days
Study: NCT06487039
Drug: EB-203
Normalized name: EB-101
DrugBank: Prademagene zamikeracel (DB17895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive EB-203 according to the following dosage and administration method for each treatment group.
Study: NCT05646550
Drug: CC-1 Infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short term (3h) infusion of CC-1
Study: NCT04706598
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for Infusion (Intravesical)